Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* B-cell chronic lymphocytic leukemia (a) Rai stage 0-II with indication for treatment by NCI Working Group Criteria: or (b) Rai stage III or IV.~* Received a minimum of one prior chemotherapy regimen. Prior treatment with corticosteroids, immunotherapies, monoclonal antibodies or radiation therapy is permitted.~* White blood cell count \> 25 x 10\^9/L~* ECOG 0, 1,or 2.~* Adequate renal and hepatic function~* Platelets \> 75 x 10\^9/L, transfusion independent.~* Neutrophils \> 1.0 x 10\^9/L, transfusion independent~Exclusion Criteria:~* Documented prolymphocytic leukemia (PLL; prolymphocytes, 55% in blood)~* Active cardiovascular disease as defined by NYHA class III-IV categorization.~* Intercurrent illness or medical condition precluding safe administration of ribavirin.~* Concurrent use of chronic steroids, except as replacement therapy for adrenal insufficiency~* Known infection with HIV, Hepatitis B or C.~* Concurrent malignancy (other than resected basal or squamous cell skin cancers or in-situ carcinoma).~* Received any previous therapy for CLL within 28 days prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Gleevec Chlorambucil

Based on this trial design, predict the completion outcome and termination type (if applicable).